A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Exclusion Criteria

• •Use of any other investigational drug in another clinical study or a post-marketing clinical study within 120 days before the administration of the study drug
• •Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment.
• •Any surgical intervention (including tooth extraction) or trauma within 90 days before hospitalization until the administration, or plan of any surgical intervention within 10 week after the final administration
• •A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG
• •PT or aPTT on blood coagulation tests outside the upper or lower reference limits (PT: 9.9 to 15.4 sec.; aPTT: 22.5 to 49.5 sec.)
• •Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before the study
• •Concurrent or previous hepatic disease (e.g. viral hepatitis, drug-induced liver injury)
• •Concurrent or previous heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring treatment)
• •Concurrent or previous respiratory disease (e.g. serious bronchial asthma, chronic bronchitis; except for a history of childhood asthma)
• •Concurrent or previous renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis; except for a history of calculus)
• •Concurrent or previous malignant tumor
• •Excessive smoking or drinking habit \[measure of "excessive": alcohol: average 45 g/day (a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake contains 22 g of alcohol), smoking: average 20 cigarettes/day\]
• •Previous treatment with YM150